Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q16518: Variant p.Tyr318Asn

Retinoid isomerohydrolase
Gene: RPE65
Feedback?
Variant information Variant position: help 318 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Tyrosine (Y) to Asparagine (N) at position 318 (Y318N, p.Tyr318Asn). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from large size and aromatic (Y) to medium size and polar (N) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In LCA2; severely decreased retinol isomerase activity. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 318 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 533 The length of the canonical sequence.
Location on the sequence: help KYLNNKYRTSPFNLFHHINT Y EDNGFLIVDLCCWKGFEFVY The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         KYLNNKYRTSPFNLFHHINTYEDNGFLIVDLCCWKGFEFVY

                              KYLNNKYRTSSFNLFHHINTYEDNEFLIVDLCCWKGFEFVY

Mouse                         KYFNNKYRTSPFNLFHHINTYEDNGFLIVDLCCWKGFEFVY

Rat                           KYFNNKYRTSPFNLFHHINTYEDNGFLIVDLCCWKGFEFVY

Bovine                        KYINNKYRTSPFNLFHHINTYEDHEFLIVDLCCWKGFEFVY

Chicken                       RLLNIKYRTSAFNLFHHINTFEDNGFLIVDLCTWKGFEFVY
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 2 – 533 Retinoid isomerohydrolase
Binding site 313 – 313
Lipidation 329 – 329 S-palmitoyl cysteine; in membrane form
Lipidation 330 – 330 S-palmitoyl cysteine; in membrane form
Mutagenesis 313 – 313 H -> A. Decreasing protein levels. Loss of enzymatic activity. Significantly decreased protein stability.
Mutagenesis 330 – 330 C -> T. Does not affect isomerohydrolase activity.



Literature citations
Leber congenital amaurosis - a model for efficient genetic testing of heterogeneous disorders: LXIV Edward Jackson Memorial Lecture.
Stone E.M.;
Am. J. Ophthalmol. 144:791-811(2007)
Cited for: VARIANTS LCA2 ILE-101; SER-118; PRO-162; ASN-318; 402-TRP--SER-533 DEL; PRO-408; ALA-443; 460-TRP--SER-533 DEL AND THR-533; Predicting the pathogenicity of RPE65 mutations.
Philp A.R.; Jin M.; Li S.; Schindler E.I.; Iannaccone A.; Lam B.L.; Weleber R.G.; Fishman G.A.; Jacobson S.G.; Mullins R.F.; Travis G.H.; Stone E.M.;
Hum. Mutat. 30:1183-1188(2009)
Cited for: CHARACTERIZATION OF VARIANTS LCA2 SER-40; GLN-44; GLN-91; TRP-91; ILE-101; ASP-239; ASN-318; PRO-408 AND VAL-434; CHARACTERIZATION OF VARIANT LYS-321; CHARACTERIZATION OF VARIANT RP20 THR-294;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.